05/06/2009
https://www.congress.gov...
"In 2018, I chaired a hearing of the Senate Aging Committee on why the costs of insulin was so high."
"I think we have a very strange system here because--to say the least, because most of us would think that the rebate, the discount that is negotiated by the PBMs, would largely benefit the consumer at..."
"What we found was a system of getting insulin from the manufacturer to the customer that was rife with perverse incentives, convoluted and opaque."
"The problem with that explanation is insurance is based on the principle that the healthy are subsidizing the sick."